Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095202 Target Snapshot

Troponin, cardiac muscle · PROTEIN COMPLEX · Homo sapiens

276Compounds
2Assays
0Approved Drugs
276.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P63316. Start with amyotrophic lateral sclerosis, then reuse UniProt P63316 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with amyotrophic lateral sclerosis, then reuse UniProt P63316 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
amyotrophic lateral sclerosis

Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with amyotrophic lateral sclerosis because it currently carries late clinical support. Linked drugs include LEVOSIMENDAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Troponin, cardiac muscle as ChEMBL target CHEMBL2095202, mapped to UniProt P63316. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Troponin, cardiac muscle
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095202
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P63316
Troponin C, slow skeletal and cardiac muscles
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Troponin, cardiac muscle is the right protein anchor across sources, using UniProt P63316 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why amyotrophic lateral sclerosis is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTroponin C, slow skeletal and cardiac muscles
UniProt AccessionP63316
Component TypeProtein
Sequence Length161 aa

Troponin C, slow skeletal and cardiac muscles

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Troponin, cardiac muscle, mapped to UniProt P63316. ChEMBL maps the protein component as Troponin C, slow skeletal and cardiac muscles. Sequence length is 161 aa.

Mapped IDP63316
Review nameTroponin, cardiac muscle
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Troponin, cardiac muscle shows late clinical disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
amyotrophic lateral sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Late clinical Phase III
cardiovascular disease
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Late clinical Phase III
congestive heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Late clinical Phase III
heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Late clinical Phase III
severe acute respiratory syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Late clinical Phase III
Shock
1 linked drug · 1 direct · 1 efficacy
Linked drugLEVOSIMENDAN
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with amyotrophic lateral sclerosis because it currently carries late clinical support. Linked drugs include LEVOSIMENDAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseamyotrophic lateral sclerosis
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5032.0
EC50244.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1581326 6.78 EC50 165.07 Preclinical
CHEMBL3195681 6.78 EC50 164.57 Preclinical
CHEMBL3195851 6.72 EC50 190.67 Preclinical
CHEMBL1468444 6.55 EC50 278.85 Preclinical
CHEMBL1379673 6.54 EC50 286.87 Preclinical
CHEMBL1477915 6.4 EC50 396.99 Preclinical
CHEMBL1398812 6.38 EC50 413.02 Preclinical
CHEMBL1369691 6.3 EC50 500.48 Preclinical
CHEMBL1573529 6.29 EC50 515.79 Preclinical
CHEMBL210208 6.25 IC50 558.14 Preclinical
Distribution

pChEMBL Value Distribution

35
5.0
29
5.5
12
6.0
5
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

2
Total Assays
118
Tested Compounds
1
Assay Types
Binding — 2 assays, 118 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 2 118 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine